Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00818337 · ClinicalTrials.gov registry record · Phase 4
Aspirin Responsiveness in Women at Risk for Cardiac Events
A Phase 4 study, sponsored by Creighton University.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT00818337 is a Phase 4 study that has completed, run by Creighton University. The registered enrollment target is 36 participants.
The verdict
NCT00818337, a Phase 4 study, has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be measured with the VerifyNow device (Accumetrics; San Diego, CA). Those women identified as biologically resistant will be switched to aspirin 325 mg for 14 days and then re-tested for aspirin responsiveness.
Interventions
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00818337
The ClinicalTrials.gov registry entry for NCT00818337 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creighton University, which has 98 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aspirin is the first listed.
NCT00818337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00818337 about?
NCT00818337 is a clinical study titled "Aspirin Responsiveness in Women at Risk for Cardiac Events". The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be measured with the VerifyNow device (Accumetrics; San Diego, CA). Those women identified as biologically resistant ...
What is the current status of trial NCT00818337?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2008-11. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00818337?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT00818337?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.